Health care professionals and researchers from around the world will
be gathering in San Francisco, California, this weekend to discuss the
latest advances in the diagnosis, treatment, and management of
gastrointestinal (GI) cancers at the 2015 GI Cancers Symposium.
More than 800 abstracts will be presented at the meeting, highlighting
research into cancers of the colon/rectum, stomach, pancreas, esophagus,
small intestine, and anus.
Two of these studies looked
at combining chemotherapy and targeted therapy for metastatic
colorectal cancer. One study compared two different chemotherapy
regimens (combinations of drugs) plus the targeted therapy drug
bevacizumab (Avastin) as initial treatment for metastatic colorectal
cancer. In the other study, researchers looked at adding the targeted
therapy ramucirumab (Cyramza) to standard chemotherapy for patients with
metastatic colorectal cancer that had gotten worse after initial
treatment. The researchers found that both the newer approach to
chemotherapy and the new targeted therapy helped patients with
metastatic colorectal cancer live longer. These studies highlight
potential new options for patients with metastatic colorectal cancer
whether they are first diagnosed and receiving initial treatment or have
had the disease worsen during treatment.
A third study that
will be highlighted at the meeting suggests that people with rectal
cancer who have no signs of cancer after receiving both chemotherapy and
radiation therapy may be able to safely postpone or not have surgery.
This could help many patients avoid the risks of rectal cancer surgery,
which can include bowel problems and decreased sexual function.
“We believe that our results will encourage more doctors to consider
this watch-and-wait approach as an alternative to immediate rectal
surgery, at least for some patients,” said senior study author Philip
Paty, MD, a surgical oncologist at the Memorial Sloan Kettering Cancer
Center in New York. “From my experience, most patients are willing to
accept some risk to defer rectal surgery in hope of avoiding major
surgery and preserving rectal function.”
It is important to talk about all of your treatment options with your
doctor. Discussing the risks and benefits of each option and how any
side effects can be managed can help you and your doctor choose the most
appropriate treatment plan for your situation.
This site is for information on the various Chemo treatments and Stem Cell Therapies since 1992. This journey became bitter sweet in 2014, with the passing of my beautiful and dear wife. Sherry, had fought Non - Hodgkins Lymphoma(NHL) since 1990, in and out of remissions time and time again. From T-Cell therapies(1990's) to Dual Cord Blood Transplant(2014), she was in Clinical Trials over the years. This site is for informational purpose only and is not to promote the use of certain therapies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment